Uncategorized Archives - Page 48 of 249

WednesdayFeb 23, 2022 10:15 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Optimistic About its Expanded DehydraTECH Investigations; Plans for More Studies in 2022

Lexaria just announced ground-breaking findings from its recently-concluded Sildenafil animal study The success of this study sets the stage for various other studies on the use of the company’s patented DehydraTECH technology The company is set to commence dosing its most extensive hypertension study in April 2022, with results expected in Q3 2022 Its successful completion could greatly enhance Lexaria’s leadership position in the global drug delivery market Lexaria Bioscience (NASDAQ: LEXX) kicked off the 2022 calendar year by receiving independent review board approval for its upcoming DehydraTECH(TM)-CBD human hypertension study, HYPER-H21-4. Additionally, in what marks another critical milestone, the…

TuesdayFeb 22, 2022 9:45 am

American Cannabis Partners Eyeing Federal Landscape as 2022 Looms Large for Cannabis Legislation

Four cannabis bills introduced on federal level indicates import to government leaders. Increased compromise, bipartisanship could lead to significant changes. ACP is strengthening position in the sector, currently operating in two states that have passed legislation approving the substance. Federal cannabis reform has been a roller coaster ride over the past several years, with the introduction of several bills raising hopes for legislative support, especially with a change in the White House seeming to create a more cannabis-friendly atmosphere. But 2021 didn’t bring the much-anticipated change, and many companies operating in the space, including American Cannabis Partners (“ACP”), are looking…

FridayFeb 18, 2022 9:30 am

Flora Growth Corp. (NASDAQ: FLGC) Focused On Opportunities in the CBD Industry to Scale Operations

Luis Merchan, Flora Growth’s President and CEO, appeared on a webinar on February 11, 2022, highlighting the opportunities and challenges affecting the CBD industry in key markets He has reiterated the company’s commitment to leveraging the industry’s opportunities for the growth of its operations, expansion of its market reach, and value creation for its shareholders The CBD industry is projected to be valued at $20 billion by 2025, and Flora Growth plans to capitalize on this growth In 2020, CBD sales in the United States reached $4.6 billion. It is projected that by 2024, this industry will be valued at…

WednesdayFeb 16, 2022 11:25 am

Following Successful Sildenafil Animal Study, Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Plans for More Studies in 2022

Lexaria’s animal study could be the first step to developing faster and better acting sildenafil oral formulations The most prominent study for Lexaria in 2022 is HYPER-H21-4, investigating patented DehydraTECH(TM)-CBD for hypertension and heart disease Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced positive findings in an animal study that evaluated DehydraTECH(TM) processing of the phosphodiesterase inhibitor (PDE5 inhibitor) sildenafil as potential use for erectile dysfunction management. A clear trend emerged during the course of the study – a faster and higher overall delivery of sildenafil into the bloodstream (https://cnw.fm/SOjPD). During the animal study, it…

MondayFeb 14, 2022 9:45 am

Flora Growth Corp. (NASDAQ: FLGC) Seeks EUA to Test Cannabis Product Against COVID Virus, Building on Early Study Results as it Names New Chief Strategy Officer

Recent research efforts have targeted the potential of cannabis compounds to combat COVID-19 infection as the worldwide pandemic presses forward into its third year Perhaps most notable among the early-stage research efforts is a study by Oregon State University that found high doses of two specific cannabinoids bound to spike proteins such as COVID’S SARS-CoV-2 and inhibited their potential for infection Cannabis cultivator and brand builder Flora Growth Corp. has filed a provisional patent application for a cannabinoid-based formula that it is simultaneously seeking approval from Colombia’s food and drug regulatory authority for a study and potential clinical trial in…

FridayFeb 11, 2022 9:45 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Technology Shows Promise in Improving Performance, Speed of ED Drugs

Health and wellness drug bio-effectiveness innovator Lexaria Bioscience is advancing human testing of its patented DehydraTECH(TM) technology for the potential treatment of high blood pressure and heart disease Lexaria also recently announced that DehydraTECH boosted the speed and effectiveness of sildenafil in laboratory rats for the potential treatment of erectile dysfunction (“ED”) The company’s statement notes that DehydraTECH-processed sildenafil “delivered 74% more sildenafil into the bloodstream on average than the concentration-matched, generic control formulation” ED affects some 30 million men in the United States and is expected to affect about 322 million men worldwide by 2025 Lexaria Bioscience (NASDAQ: LEXX),…

ThursdayFeb 10, 2022 9:30 am

The Alternative Products Expo To Offer Important Networking Opportunities

The Alternative Products Expo presented by 3Chi arrives in Fort Lauderdale March 11-13 to feature the scope and potential of all innovative products and services of the alternative products ecosystem. Organized by ZJ Events, the event group is committed to bringing the industry’s best alternative products traders, vendors, and enthusiasts under one roof, while offering a fun and exciting experience. Having conducted its CBD shows in the top cities of America, ZJ Events is all set to host an exciting new event in Fort Lauderdale, The Alternative Products Expo. The alternative product category includes herbal products, mood enhancers, cannabis derivatives,…

WednesdayFeb 09, 2022 10:00 am

The New England Cannabis Convention To Be Held In Boston

Cannabis growers, traders, industry professionals, and enthusiasts are invited to attend the New England Cannabis Convention (“NECANN”), on March 18-20, 2022. NECANN events, organized since 2014 are considered as one of the largest cannabis events on the east coast. The NECANN events attract a huge number of Hemp, MMJ and Cannabis traders/professionals in the Northeast in the annual Boston Cannabis Convention. These events are the home base for the New England cannabis industry. The New England Cannabis Convention in Boston offers a viable avenue for learning the intricacies of the Cannabis Industry and establishing networking and communication among cannabis growers,…

WednesdayFeb 09, 2022 9:45 am

American Cannabis Partners Committed to Sustainable Business Practices

Top companies recognize the “massive opportunity of sustainability” Consumers are becoming increasingly aware and supportive of companies working to make a difference ACP follows an organic cultivation model that includes the implementation of sustainable operating practices Sustainability is a growing concern — and priority — for businesses in today’s environment-conscious and energy-aware world, and smart companies, including American Cannabis Partners (“ACP”), are committed to doing their part. A multistate cannabis company, ACP is committed to operating its business with a positive impact on the environment, employees and customer experience. “Companies at the top of their industries recognize the massive opportunity of sustainability…

TuesdayFeb 08, 2022 12:50 pm

Lexaria Bioscience Corp. (NASDAQ: LEXX) CEO Summarizes 2021 Milestones, Outlines 2022 Plans and Expectations, in Annual Letter to Shareholders

In 2021, Lexaria conducted several main studies evaluating DehydraTECH-processed CBD and nicotine The company has big plans for 2022, a year it expects to undertake three ground-breaking studies Lexaria hopes these three major studies will generate sufficient data to support either regulated IND-type applications or to stimulate corporate partnerships The company is eying larger national and international applications for DehydraTECH with the aim of generating revenue through licensing fees and royalties For Lexaria Bioscience (NASDAQ: LEXX), a drug delivery company whose patented DehydraTECH(TM) technology has proven effective in improving bioavailability, speed of onset, and efficiency of orally-delivered fat-soluble active molecules…